Avtor/Urednik		Gatta, G; Luksch, R; Coleman, MP; Corazziari, I; Pompe-Kirn, V
Naslov		Survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) in European children since 1978: a population-based study
Tip		članek
Vir		Eur J Cancer
Vol. in št.		Letnik 37, št. 6
Leto izdaje		2001
Obseg		str. 695-702
Jezik		eng
Abstrakt		We used data supplied by population-based cancer registries, collected and quality controlled using a common protocol, to analyse survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) among children in 17 European countries. Variations in survival in relation to age, country, histologic subtype and period of diagnosis (1978-1992) were examined. These are rare malignancies and survival can be studied reliably only by examination of data from a very large population (in this case EUROCARE). 5 years after diagnosis, overall survival was 44% (95% CI 33-55) for CML and 37% (95% CI 3243) for ANLL. For both types of leukaemia, survival was slightly better for girls and worse in children under 5 years of age. Consistent with clinical literature, the ANLL subtypes with poorer prognosis were monocytic, megakaryocytic and erythroleukaemia. For ANLL, 5-year survival was better in Finland, the UK, The Netherlands and Germany (>40%); for CML, 5-year survival was highest in Italy, although the 95% CI were wide. The risk of death from ANLL and CML fell by 7% per year and 5% per year, respectively, after adjustment for age, gender and country. Since these rare childhood malignancies were virtually untreatable until 1970, these are very welcome trends.
Deskriptorji		LEUKEMIA, LYMPHOCYTIC, ACUTE LEUKEMIA, MYELOID, CHRONIC SURVIVAL RATE TIME FACTORS SEX FACTORS REGISTRIES RESIDENCE CHARACTERISTICS PROGNOSIS EUROPE AGE FACTORS CHILD FOLLOW-UP STUDIES